High prevalence of ascorbate deficiency in an Australian peritoneal dialysis population

Nephrology

Volumn 13, Issue 1, 2008, Pages 17-22

  Singer, Richard ^c   Rhodes, Helen C ^c   Chin, George ^c   Kulkarni, Hemant ^c   Ferrari, Paolo ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b FREMANTLE HOSPITAL   (Australia)

^c NONE

Author keywords

Ascorbate; Deficiency; Nutrition; Peritoneal dialysis; Supplements

Indexed keywords

ASCORBIC ACID; MULTIVITAMIN;

ADULT; AGED; ARTICLE; AUSTRALIA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIALYSATE; DRUG BLOOD LEVEL; DRUG FORMULATION; FEMALE; FOLLOW UP; HUMAN; MALE; NUTRITIONAL ASSESSMENT; PERITONEAL DIALYSIS; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SCURVY; VITAMIN DEFICIENCY; VITAMIN SUPPLEMENTATION;

AGED; ASCORBIC ACID; ASCORBIC ACID DEFICIENCY; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PREVALENCE;

EID: 38149104799     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2007.00857.x     Document Type: Article

References (28)

1. Kallner A. Influence of vitamin C status on the urinary excretion of catecholamines in stress. Hum. Nutr. Clin. Nutr. 1983 37 : 405 11.
2. Padh H. Vitamin C: Newer insights into its biochemical functions. Nutr. Rev. 1991 49 : 65 70.
3. Peters EM, Anderson R., Nieman DC, Fickl H, Jogessar V. Vitamin C supplementation attenuates the increases in circulating cortisol, adrenaline and anti-inflammatory polypeptides following ultramarathon running. Int. J. Sports Med. 2001 22 : 537 43.
4. Patak P, Willenberg HS, Bornstein SR. Vitamin C is an important cofactor for both adrenal cortex and adrenal medulla. Endocr. Res. 2004 30 : 871 5.
5. Baker EM, Hodges RE, Hood J, Sauberlich HE, March SC, Canham JE. Metabolism of 14C- and 3H-labeled 1-ascorbic acid in human scurvy. Am. J. Clin. Nutr. 1971 24 : 444 54.
6. Reuler JB, Broudy VC, Cooney TG. Adult scurvy. JAMA 1985 253 : 805 7.
7. Hodges RE, Baker EM, Hood J, Sauberlich HE, March SC. Experimental scurvy in man. Am. J. Clin. Nutr. 1969 22 : 535 48.
8. Hodges RE, Hood J, Canham JE, Sauberlich HE, Baker EM. Clinical manifestations of ascorbic acid deficiency in man. Am. J. Clin. Nutr. 1971 24 : 432 43.
9. Levine M, Conry-Cantilena C, Wang Y et al. Vitamin C pharmacokinetics in healthy volunteers: Evidence for a recommended dietary allowance. Proc. Natl. Acad. Sci. U.S.A. 1996 93 : 3704 9.
10. Hirsch IB, Atchley DH, Tsai E, Labbe RF, Chait A. Ascorbic acid clearance in diabetic nephropathy. J. Diabetes Complications 1998 12 : 259 63.
11. Mydlik M, Derzsiova K, Svac J, Dlhopolcek P, Zemberova E. Peritoneal clearance and peritoneal transfer of oxalic acid, vitamin C, and vitamin B6 during continuous ambulatory peritoneal dialysis. Artif. Organs 1998 22 : 784 8.
12. Lee EJ, Myint CC, Tay ME, Yusuf N, Ong CN. Serum ascorbic acid and protein calorie malnutrition in continuous ambulatory peritoneal dialysis patients. Adv. Perit. Dial. 2001 17 : 219 22.
13. Lim SL, Lee EJ, Myint CC et al. Oral intake and serum levels of ascorbic acid in continuous ambulatory peritoneal dialysis patients. Adv. Perit. Dial. 2001 17 : 215 18.
14. Shah GM, Ross EA, Sabo A, Pichon M, Bhagavan H, Reynolds RD. Ascorbic acid supplements in patients receiving chronic peritoneal dialysis. Am. J. Kidney Dis. 1991 18 : 84 90.
15. Pru C, Eaton J, Kjellstrand C. Vitamin C intoxication and hyperoxalemia in chronic hemodialysis patients. Nephron 1985 39 : 112 16.
16. Mydlik M, Derzsiova K. Renal replacement therapy and secondary hyperoxalemia in chronic renal failure. Kidney Int. Suppl. 2001 78 : S304 7.
17. Yamauchi A, Fujii M, Shirai D et al. Plasma concentration and peritoneal clearance of oxalate in patients on continuous ambulatory peritoneal dialysis (CAPD). Clin. Nephrol. 1986 25 : 181 5.
18. Morgan SH, Maher ER, Purkiss P, Watts RW, Curtis JR. Oxalate metabolism in end-stage renal disease: The effect of ascorbic acid and pyridoxine. Nephrol. Dial Transplant 1988 3 : 28 32.
19. Costello JF, Sadovnic MJ, Cottington EM. Plasma oxalate levels rise in hemodialysis patients despite increased oxalate removal. J. Am. Soc. Nephrol. 1991 1 : 1289 98.
20. Fayemi AO, Ali M, Braun EV. Oxalosis in hemodialysis patients: A pathologic study of 80 cases. Arch. Pathol. Laboratory Med. 1979 103 : 58 62.
21. Tomson CR, Channon SM, Parkinson IS et al. Correction of subclinical ascorbate deficiency in patients receiving dialysis: Effects on plasma oxalate, serum cholesterol, and capillary fragility. Clin. Chim. Acta 1989 180 : 255 64.
22. Marangella M, Bagnis C, Bruno M, Petrarulo M, Gabella P, Linari F. Determinants of oxalate balance in patients on chronic peritoneal dialysis. Am. J. Kidney Dis. 1993 21 : 419 26.
23. Parry GJ, Bredesen DE. Sensory neuropathy with low-dose pyridoxine. Neurology 1985 35 : 1466 8.
24. Ching SY, Prins AW, Beilby JP. Stability of ascorbic acid in serum and plasma prior to analysis. Ann. Clin. Biochem. 2002 39 : 518 20.
25. Mydlik M, Derzsiova K, Valek A, Szabo T, Dandar V, Takac M. Vitamins and continuous ambulatory peritoneal dialysis (CAPD). Int. Urol. Nephrol. 1985 17 : 281 6.
26. Garcia-Bravo B, Rodriguez-Pichardo A, Camacho F. Uraemic follicular hyperkeratosis. Clin. Exp. Dermatol. 1985 10 : 448 54.
27. de la Rosa Garcia E, Mondragon Padilla A, Aranda Romo S, Bustamante Ramirez MA. Oral mucosa symptoms, signs and lesions, in end stage renal disease and non-end stage renal disease diabetic patients. Med. Oral Patol. Oral Cir. Bucal. 2006 11 : E467 73.
28. Shouda J, Nakamoto H, Sugahara S, Okada H, Suzuki H. Incidence of gingival hyperplasia caused by calcium antagonists in continuous ambulatory peritoneal dialysis patients. Adv. Perit. Dial. 1999 15 : 153 5.